(TheNewswire)
Toronto, Ontario / TheNewswire / March 19,
2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”,
TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it successfully showcased the
next-generation VMS+3.0 system at the American College of Cardiology’s 68th
Annual Scientific Session & Expo.
With nearly 20,000 cardiologists from around the world attending the ACC’s Annual Scientific
Sessions & Expo, it provided an opportunity to give live hands-on demonstrations in the Ventripoint booth to a highly captivated
audience.
“Attending the global marketplace for cardiovascular innovation gave us the forum to showcase the
VMS+ 3.0 system to attending cardiologists, along with discussions for technology industry partnerships. It is evident there is a
clear need for accurate volumetric measurements for right ventricular function. We have scheduled a number of follow-up meetings at
both pediatric and adult cardiac centers,” notes Jessica Naman, Marketing Manager at Ventripoint Diagnostics.
The VMS+3.0 system is designed to use standard 2D echo images to provide a streamlined approach for
volumetric measurements and ejection fractions for all 4 chambers of the heart. The compact and portable system can be set-up
within minutes. It has an interactive guided workflow embedded in the system to highlight view capture and point
placement on each view to increase efficiency and ease of use while performing imaging and analysis. The
system uses a new patent-pending position sensor, which allows the patient to re-position during the imaging portion of the
exam.
The VMS+3.0 system is not commercially available for sale. For investigational use only.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based
Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the
first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has
developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac
care.
For further information please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of
applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing",
"may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking
information or statements. The forward-looking statements and information are based on certain key expectations and assumptions
made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking
statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and
information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking
statements and information address future events and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other
factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most
recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news
release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news
release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any
forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required
by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2019 TheNewswire - All rights reserved.